- Home
- ELS vs MDGL Comparison
ELS vs MDGL Comparison
Compare ELS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELS | MDGL |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 12.5B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELS | MDGL |
|---|---|---|
| Price | $60.94 | $515.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $70.88 | ★ $580.77 |
| AVG Volume (30 Days) | ★ 1.4M | 319.8K |
| Earning Date | 01-26-2026 | 02-25-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ 2.36 | N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $1,535,911,000.00 | $740,640,000.00 |
| Revenue This Year | $1.02 | $435.63 |
| Revenue Next Year | $4.46 | $52.56 |
| P/E Ratio | $30.52 | ★ N/A |
| Revenue Growth | 0.93 | ★ 864.21 |
| 52 Week Low | $58.15 | $265.00 |
| 52 Week High | $70.35 | $615.00 |
Technical Indicators
Market Signals| Indicator | ELS | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 34.03 |
| Support Level | $59.37 | $532.45 |
| Resistance Level | $61.62 | $589.98 |
| Average True Range (ATR) | 0.82 | 22.89 |
| MACD | -0.02 | -8.88 |
| Stochastic Oscillator | 65.55 | 1.07 |
Price Performance
Historical ComparisonAbout ELS Equity Lifestyle Properties Inc.
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 455 properties across the US with a higher concentration in the Sunbelt region with 38% of the company's properties located in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations with over 70% of the company's properties either being age-restricted or having an average resident age over 55.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.